1
Yun He, Tao Jiang, Kelli L Kuhen, David Archer Ellis, Baogen Wu, Tom Yao Hsiang Wu, Badry Bursulaya: Oxindoles with anti-HIV activity. IRM, Emily Tongro Wu, Genomics Institute of the Novartis Research Foundation, April 17, 2007: US07205328 (9 worldwide citation)

The present invention relates to inhibition of viruses, e.g., HIV using oxindoles and compounds related to oxindoles. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions that inhibit HIV in a cell; as well as to methods of prophyl ...


2
Hong Liu, David Tully, Robert Epple, Badry Bursulaya, Jennifer Williams, Arnab Chatterjee, Jennifer Leslie Harris, Jun Li: Inhibitors of cathepsin S. IRM, Townsend and Townsend and Crew, September 19, 2006: US07109243 (6 worldwide citation)

The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme (e.g., cathespin K). The present invention also provides methods for tre ...


3
David C Tully, Arnab K Chatterjee, Agnes Vidal, Hank Michael James Petrassi, Zhiwei Wang, Badry Bursulaya, Glen Spraggon: Compounds and compositions as channel activating protease inhibitors. IRM, Emily Tongco Wu, Genomics Institute of the Novartis Research Foundation, May 31, 2011: US07951823 (2 worldwide citation)

The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for, using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prosta ...


4
David C Tully, Arnab K Chatterjee, Hank Michael James Petrassi, Badry Bursulaya, Glen Spraggon: Compounds and compositions as channel activating protease inhibitors. IRM, Emily Tongco Wu, Genomics Institute of the Novartis Research Foundation, May 10, 2011: US07939547 (2 worldwide citation)

The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prostas ...


5
Hong Liu, Phil Alper, Arnab Chatterjee, David Tully, Badry Bursulaya, David Woodmansee, Robert Epple, Jennifer Leslie Harris, Jun Li: Inhibitors of cathepsin S. IRM, Emily Tongco Wu, Genomics Institute of the Novartis Research Foundation, June 10, 2008: US07384970 (1 worldwide citation)

The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease stat ...


6
Thomas H Marsilje, Wenshuo Lu, Bei Chen, Xiaohui He, Badry Bursulaya, Christian Cho Hua Lee: 2-biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors. IRM, Emily Tongco Wu, Genomics Institute of the Novartis Research Foundation, May 14, 2013: US08440681

The invention provides novel pyrimidine derivatives of formula (1) and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-l ...


7
David C Tully, Amab K Chatterjee, Agnes Vidal, Hank Michael James Petrassi, Zhiwei Wang, Badry Bursulaya, Glen Spraggon: Compounds and compositions as channel activating protease inhibitors. IRM, Emily Tongco Wu, Genomics Institute of the Novartis Research Foundation, December 25, 2012: US08338469

The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for, using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prosta ...


8
Gerald Lelais, Robert Epple, Thomas H Marsilje III, Pierre Yves Michellys, Matthew McNeill, Yun Long, Wenshuo Lu, Bei Chen, Badry Bursulaya, Songchun Jiang: Compounds and compositions for modulating EGFR Activity. Novartis, Emily T Wu, Genomics Institute of the Novartis Research Foundation, September 13, 2016: US09440957

The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating EGFR activity, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated EGFR activity.


9
Badry Bursulaya, Dai Cheng, Jiqing Jiang, Donald S Karanewsky, Yi Liu, Shifeng Pan, Yongqin Wan, Xia Wang, Yun Feng Xie, Yang Yang: Compounds and compositions as ITPKb inhibitors. IRM, Daniel E Raymond, Genomics Institute of the Novartis Research Foundation, May 15, 2012: US08178526

The invention provides a novel class of compounds of formula (I), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or dysregulated B cell activities, particularly diseases or disorders that in ...


10
Bernhard Hubert Geierstanger, Jan Grunewald, Badry Bursulaya: Site-specific labeling methods and molecules produced thereby. Novartis, March 7, 2017: US09585970

The present invention provides methods of site-specific labeling of antibodies, using proteins having 4′-phosphopantetheinyl transferase activity that catalyze post-translational modification of peptide sequences (“peptide tags”) incorporated into one or more specific sites of an antibody of interes ...